Solasia kondigt lancering van Darvias® in Japan aan
TOKIO–(BUSINESS WIRE)– Solasia Pharma K.K. (TOKYO:4597, Hoofdkantoor: Tokio, Japan, President & CEO: Yoshihiro Arai, hierna “Solasia”) heeft vandaag officieel aangekondigd dat een organoarsenicum “DARVIAS® Injection 135mg” (SP-02, hierna DARVIAS®) vandaag is gelanceerd in Japan voor gebruik bij recidiverend of refractair perifeer T-cellymfoom. DARVIAS® zal op de markt worden gebracht door Nippon Kayaku Co., Ltd. (TOKYO:4272, hoofdkantoor: Tokio, Japan, president: Atsuhiro Wakumoto).
Bekijk de bronversie op businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/
Solasia Announces Launch of Darvias® in Japan
TOKYO–(BUSINESS WIRE)– Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/
Contacts
Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
Tel: +81 3 5843 8046 (TOKYO)